PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare ...

Final CMS rule concludes iovera is a qualifying device for separate payment under the NOPAIN Act ---- Beginning January 1, 2025, providers can ...

Drug–ligand conjugates and ligand-anchored carrier systems encapsulating drug/gene have been developed and well characterized for the purpose of targeted breast cancer therapy. Liposomes serve ...

Intrinsic Tumor Drivers and Immune Escape Mechanisms in CD19 CAR T-Cell Therapy Resistance for Aggressive Large ...

Alkermes plc announced today that management will participate at two upcoming investor conferences. Stifel Healthcare ConferenceDate/Time: Monday, Nov. 18, 2024 at 8:35 a.m. ET (1:35 p.m. GMT) ...

Innocan Pharma Corporation ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, announced that it has taken the strategic decision to focus its development ...

Operator: Good day, and welcome to the Third Quarter 2024 Pacira Biosciences Inc. Earnings Conference Call. At this time, all ...

This article highlights several inspiring men and women working across academia and industry who are breaking barriers and ...

Application of these bio-inspired drug delivery systems include photodynamic therapy ... Liposome functionalization with copper-free “click chemistry”. Journal of Controlled Release, 202, 14-20.

and it may be related to the inhibition of differentiation of primitive progenitor cells by the fusion gene. Patients with SET-CAN/NUP214 fusion usually exhibit resistance to chemotherapy, including ...